-transparent.png){kind=logo}
The effect of platelet factor 4 (PF4) on myoblast cultures with or without basic fibroblast growth factor (bFGF) or other growth factors was investigated in the present in vitro experiments, with reference to bFGF binding to myoblast membrane fraction. When PF4 was added to the culture medium 1 day after myoblast cultivation, the nuclei of both myoblasts and myotubes were markedly reduced in number in a dose-dependent manner, whereas the inhibitory effect of PF4 on myoblast development was not observed when PF4 was added to the culture medium 3, 7, or 14 days after myoblast cultivation. In contrast, bFGF significantly increased the numbers of myoblast and myotube nuclei. When bFGF and PF4 were simultaneously added to the culture medium, PF4 abolished the facilitatory effects of bFGF on myogenesis. The real-time biospecific interaction analysis (BLA) core system showed that the myoblast membrane fraction at 1 day after cultivation contains bFGF-binding elements which are blocked by PF4 in a dose-dependent manner. Moreover, [126I]-bFGF binding experiments indicated the existence of both high and low affinity binding sites on myoblast membranes, although the high affinity binding sites decreased in number and the dissociation constant increased in value as the culture period was prolonged. Among the six other growth factors examined, acidic fibroblast growth factor and platelet-derived growth factor-BB stimulated myogenesis, and their effects were blocked by PF4 treatment. These findings suggest that: 1) PF4 inhibits myoblast proliferation and myotube formation only for a limited initial period of cultivation, possibly because of the time-dependent down-regulation of high affinity bFGF receptors: and 2) PF4 may be used as a tool to investigate the function of endogenous heparin-binding growth factors upregulated transiently at a certain developmental stage or in case of tissue damage and repair, even though it is not monospecific to bFGF.
H Peng, and
T C Wen, and
K Igase, and
J Tanaka, and
S Matsuda, and
J Aburaya, and
M Sakanaka
July 1994,
The Journal of clinical investigation,
H Peng, and
T C Wen, and
K Igase, and
J Tanaka, and
S Matsuda, and
J Aburaya, and
M Sakanaka
June 2017,
Gene,
H Peng, and
T C Wen, and
K Igase, and
J Tanaka, and
S Matsuda, and
J Aburaya, and
M Sakanaka
July 1998,
British journal of cancer,
H Peng, and
T C Wen, and
K Igase, and
J Tanaka, and
S Matsuda, and
J Aburaya, and
M Sakanaka
June 1997,
Investigative ophthalmology & visual science,
H Peng, and
T C Wen, and
K Igase, and
J Tanaka, and
S Matsuda, and
J Aburaya, and
M Sakanaka
February 2015,
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
H Peng, and
T C Wen, and
K Igase, and
J Tanaka, and
S Matsuda, and
J Aburaya, and
M Sakanaka
November 1994,
Biochemistry,
H Peng, and
T C Wen, and
K Igase, and
J Tanaka, and
S Matsuda, and
J Aburaya, and
M Sakanaka
February 1999,
Experimental neurology,
H Peng, and
T C Wen, and
K Igase, and
J Tanaka, and
S Matsuda, and
J Aburaya, and
M Sakanaka
November 1991,
Cancer research,
H Peng, and
T C Wen, and
K Igase, and
J Tanaka, and
S Matsuda, and
J Aburaya, and
M Sakanaka
May 2011,
Tissue engineering. Part A,
H Peng, and
T C Wen, and
K Igase, and
J Tanaka, and
S Matsuda, and
J Aburaya, and
M Sakanaka
November 1999,
Nihon rinsho. Japanese journal of clinical medicine,
